1,2,3,4-Tetramethylpyrrol | 70319-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1,2,3,4-Tetramethylpyrrol
• 英文别名: 1,2,3,4-Tetramethylpyrrole
• CAS: 70319-55-0
• 化学式: C₈H₁₃N
• 分子量: 123.198
• InChiKey: RTNZJPRTDBSPHO-UHFFFAOYSA-N

物化性质

• 沸点：
  196.7±9.0 °C(Predicted)
• 密度：
  0.88±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1,2,3,4-Tetramethylpyrrol 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙酸酐 作用下， 生成 3-ethyl-2-[4-(1,3,4,5-tetramethyl-pyrrol-2-yl)-buta-1,3-dienyl]-benzoxazolium; iodide
  参考文献：
  名称：

  Mordanting basic dyes in photography

  摘要：

  公开号：

  US02756149A1
• 作为产物：
  描述：

  2,4-二甲基-3-吡咯羧酸乙酯 以0.32 g (53%)的产率得到1,2,3,4-Tetramethylpyrrol
  参考文献：
  名称：

  Alkylation process

  摘要：

  取代吡咯类化合物，如3-乙基-4-甲基-5-羰基乙酸酯吡咯、2,4-二甲基-3-乙酰基吡咯和2-甲基-5-羧基吡咯-4-丙酸二乙酯，可通过与醛或酮在存在酸性缩合剂（如碘化氢）和兼容的还原剂（如金属锌或氯化亚锡）的情况下进行一步反应进行烷基化。适合的羰基反应物包括甲醛、对甲醛、异丁醛、丙酮、环己酮和甲基异丁基酮。本申请是美国1972年8月18日申请的第281,624号专利申请的继续申请，该专利申请已被放弃，是美国1969年6月10日申请的第832,001号专利申请的续展部分申请。

  公开号：

  US04070366A1

文献信息

• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：UNIVERSAL DISPLAY CORPORATION

  公开号：US20200369699A1

  公开（公告）日：2020-11-26

  Provided is a compound comprising a first ligand L A of

  提供一个包含第一配体L的化合物。
• HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
  申请人：GiraFpharma LLC

  公开号：US20190023666A1

  公开（公告）日：2019-01-24

  Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.

  提供了氨基吡嗪化合物作为腺苷受体的调节剂。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂，并且可能在肿瘤学中发挥特定作用。
• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
  申请人：INTEGRAL BIOSCIENCES PVT LTD

  公开号：WO2020012357A1

  公开（公告）日：2020-01-16

  The present invention discloses compounds useful in treatment of conditions associated with excessive activity of transforming growth factor beta (TGF-β), particularly type 1 or activin-like kinase 5 (ALK 5). Specifically the present invention discloses compound of formula (I) which exhibit inhibitory activity against ALK 5. Method of treating conditions associated with excessive activity (ALK 5) with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

  本发明揭示了在治疗与转化生长因子β（TGF-β）过度活性相关的疾病中有用的化合物，特别是针对类型1或类活化激酶5（ALK 5）。具体来说，本发明揭示了具有对ALK 5具有抑制活性的化合物的结构式（I）。还公开了使用这种化合物治疗与过度活性（ALK 5）相关的疾病的方法。此外，还公开了这些化合物的用途、制药组合物和试剂盒。
• HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF
  申请人：iOmx Therapeutics AG

  公开号：EP3901151A1

  公开（公告）日：2021-10-27

  The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions disclosed herein may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

  该发明涉及激酶抑制剂，特别是蛋白激酶的抑制剂，包括SIK家族CSF1R，ABL/BCR-ABL，SRC，HCK，PDGFR，KIT和/或它们的突变体。尽管在结构上类似于达沙替尼，但该发明的激酶抑制剂具有独特之处；具有一类特殊的卤代杂环芳基。这种激酶抑制剂可能表现出与达沙替尼和其他在结构上相似的激酶抑制剂不同的某些性质。该发明的激酶抑制剂或包含它们的药物组合物可用于治疗某种疾病或病况，例如增生性疾病，例如白血病或实体肿瘤。特别是，这些和其他在结构上相似的激酶抑制剂可用于治疗增生性疾病 - 例如混合表型急性白血病（MPAL）- 其特征包括MEF2C蛋白的存在，11q23处的人类染色体易位，和/或KMT2A融合致癌蛋白。本文披露的激酶抑制剂或药物组合物可用于局部调节受试者的皮肤色素沉着，例如赋予UV保护并降低皮肤癌风险。
• (Hetero)Cyclycarboxamides for Controlling Pathogenic Fungi
  申请人：Gewehr Markus

  公开号：US20070275981A1

  公开（公告）日：2007-11-29

  The invention relates to the use of (hetero)cyclylcarboxamides of general formula (I) and to the agriculturally useful salts thereof for controlling plant pathogenic fungi, the variables in formula (I) having the following designations: A represents phenyl or an at least monosaturated five-membered or six-membered heterocycle with 1, 2 or 3 heteroatoms as ring members selected from N, O, S, S(═O) and S(═O) 2 , where phenyl and the at least monosaturated five-membered or six-membered heterocycle can be unsubstituted or substituted according to the description; Y represents oxygen or sulphur; R 1 represents H, OH, alkyl, cycloalkyl, alkoxy, halogenalkyl, halogencycloalkyl or halogenalkoxy; R 2 and R 3 represent H, halogen, nitro, CN, alkyl, cycloalkyl, alkenyl, alkinyl, alkoxy, halogenalkyl, halogencycloalkyl, halogenalkenyl, halogenalkinyl or halogenalkoxy; R 4 represents halogen, nitro, CN, alkyl, cycloalkyl, alkenyl, alkinyl, alkoxy, halogenalkyl, halogencycloalkyl, halogenalkenyl, halogenalkinyl or halogenalkoxy; R 5 represents hydrogen, halogen, nitro, CN, OH, alkyl, cycloalkyl, alkenyl, alkinyl, alkoxy, alkenyloxy, alkinyloxy, alkoxyalkoxy, halogenalkyl, halogencycloalkyl, halogenalkenyl, halogenalkinyl or halogenalkoxy; alklthio, halogenalkylthio, alkylsulfinyl, halogenalkylsulfinyl, alkylsulfonyl, halogenalkylsulfonyl, —(CR 6 )═NOR 7 , —C(O)R 8 , NR 9 R 10 , —C(O)NR 9 R 10 , —C(S)NR 9 R 10 , phenyl or phenylalkyl, the phenyl ring in the last two radicals optionally comprising between 1 and 4 of the radicals cited for R 4 ; R 6 , R 7 , R 8 , R 9 and R 10 have the designations cited in the description; the two radicals R 4 and R 5 bound to adjacent carbon atoms can also represent an alkylene chain with 3 to 5 members, wherein 1 or 2 non-adjacent CH 2 groups can also be replaced by O or S, and part or all of the hydrogens can be replaced by halogen; Ar represents phenyl, naphtyl or a five-membered or six-membered heteroaromatic radical with 1, 2 or 3 heteroatoms as ring members selected from N, O, and S, that can optionally also carry a fused benzene ring; and n represents 0, 1, 2, 3, or 4. The invention also relates to crop protection agents containing said compounds.

  该发明涉及使用一般式（I）的（杂）环戊酰胺及其在农业上有用的盐来控制植物病原真菌，式（I）中的变量具有以下符号：A代表苯或至少含有1、2或3个杂原子（N、O、S、S(═O)和S(═O)2）的五元环或六元环，其中苯和至少含有1个杂原子的五元环或六元环可以按照说明未取代或取代；Y代表氧或硫；R1代表H、OH、烷基、环烷基、烷氧基、卤代烷基、卤代环烷基或卤代烷氧基；R2和R3代表H、卤素、硝基、CN、烷基、环烷基、烯基、炔基、烷氧基、卤代烷基、卤代环烷基、卤代烯基、卤代炔基或卤代烷氧基；R4代表卤素、硝基、CN、烷基、环烷基、烯基、炔基、烷氧基、卤代烷基、卤代环烷基、卤代烯基、卤代炔基或卤代烷氧基；R5代表氢、卤素、硝基、CN、OH、烷基、环烷基、烯基、炔基、烷氧基、烯基氧基、炔基氧基、烷氧基烷氧基、卤代烷基、卤代环烷基、卤代烯基、卤代炔基或卤代烷氧基；alklthio、卤代烷硫基、烷基磺酰基、卤代烷磺酰基、烷基磺酰基、卤代烷磺酰基、—(CR6)═NOR7、—C(O)R8、NR9R10、—C(O)NR9R10、—C(S)NR9R10、苯或苯基烷基，最后两个基团中的苯环可以选择包含1到4个R4中列出的基团；R6、R7、R8、R9和R10具有说明中列出的符号；相邻碳原子上结合的两个基团R4和R5也可以代表具有3到5个成员的烷基链，其中1或2个非相邻的CH2基团也可以被O或S替换，部分或全部氢原子可以被卤素取代；Ar代表苯、萘或具有1、2或3个杂原子（N、O和S）的五元环或六元环杂芳基，也可以携带一个融合的苯环；n代表0、1、2、3或4。该发明还涉及含有上述化合物的作物保护剂。